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Abstract
A Plasmodium falciparum 3D7 strain Apical Membrane Antigen-1 (AMA1) vaccine, formulated with AS02A adjuvant, slowed
parasite growth in a recent Phase 1/2a trial, however sterile protection was not observed. We tested this AS02A, and a
Montanide ISA720 (ISA) formulation of 3D7 AMA1 in Aotus monkeys. The 3D7 parasite does not invade Aotus erythrocytes,
hence two heterologous strains, FCH/4 and FVO, were used for challenge, FCH/4 AMA1 being more homologous to 3D7
than FVO AMA1. Following three vaccinations, the monkeys were challenged with 50,000 FCH/4 or 10,000 FVO parasites.
Three of the six animals in the AMA+ISA group were protected against FCH/4 challenge. One monkey did not become
parasitemic, another showed only a short period of low level parasitemia that self-cured, and a third animal showed a delay
before exhibiting its parasitemic phase. This is the first protection shown in primates with a recombinant P. falciparum
AMA1 without formulation in Freund’s complete adjuvant. No animals in the AMA+AS02A group were protected, but this
group exhibited a trend towards reduced growth rate. A second group of monkeys vaccinated with AMA+ISA vaccine was
not protected against FVO challenge, suggesting strain-specificity of AMA1-based protection. Protection against FCH/4
strain correlated with the quantity of induced antibodies, as the protected animals were the only ones to have in vitro
parasite growth inhibitory activity of .70% at 1:10 serum dilution; immuno-fluorescence titers .8,000; ELISA titers against
full-length AMA1 .300,000 and ELISA titer against AMA1 domains1+2 .100,000. A negative correlation between log ELISA
titer and day 11 cumulative parasitemia (Spearman rank r=20.780, p value=0.0001), further confirmed the relationship
between antibody titer and protection. High titers of cross-strain inhibitory antibodies against AMA1 are therefore critical to
confer solid protection, and the Aotus model can be used to down-select future AMA1 formulations, prior to advanced
human trials.
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Introduction
A vaccine based on a recombinant circumsporozoite protein,
RTS,S was shown in a recent phase 2 clinical trial in 5–17 month
old children to have 53% vaccine efficacy against P. falciparum
malaria clinical episodes. [1]. One strategy to build on the success
of this vaccine is to combine it with other Plasmodium antigens [2].
P. falciparum Apical Membrane Antigen-1 (AMA1) is one such
promising malaria vaccine candidate [3]. AMA1 is located within
the micronemes of Plasmodium merozoites present within blood
stage schizonts. At the time of schizont rupture the AMA1 protein
gets translocated to the merozoite surface [4], where it plays a vital
role in the erythrocyte invasion process [5]. Antibodies against
AMA1 are potent inhibitors of merozoite invasion [6]. AMA1 is
also present on the surface of sporozoites and AMA1 antibodies
inhibit sporozoite invasion into hepatocytes [7].
In the first non human primate vaccine trial reported for
AMA1, three rhesus monkeys received 2 doses of an affinity
purified native P. knowlesi AMA1 protein vaccine adjuvanted with
saponin [8]. Following challenge all three control monkeys
required radical drug cure due to acute parasitemia. Two of 3
AMA1 immunized monkeys had parasitemia profiles similar to
that of the controls, but one monkey showed a brief delay in
patency followed by a self-limiting infection. Upon re-challenge, all
3 immunized animals showed near sterile protection. In a repeat
experiment, 3 monkeys received 3 doses of the AMA1 vaccine. As
in the first experiment, only 1 out of the 3 monkeys showed a
degree of protection. Hence, vaccine efficacy as measured by
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protection was 0%. Notably serum from the protected monkeys
had the highest pre-challenge parasite invasion inhibitory activity
against P. knowlesi merozoites [8].
A subsequent immunization trial used recombinant P. fragile
AMA1 in squirrel monkeys [9]. Five Saimiri (squirrel) monkeys
received 3 doses of a baculovirus-produced recombinant P. fragile
AMA1 protein vaccine adjuvanted with Montanide ISA720.
Following challenge with P. fragile blood stage parasites, all 4
control monkeys required drug treatment for high parasitemia.
Four out of the 5 AMA1 vaccinated animals showed suppressed
parasitemia profiles compared to the controls. The efficacy of this
AMA1 vaccine as measured by reduced parasite burden was 80%
and as measured by sterile protection was 0%. Serum from the one
non-protected animal had the lowest IFA titer while the two best
protected animals had the highest titer in the trial. [9].
Another trial used P. cynomolgi as a challenge parasite in
macaque monkeys [10]. Five rhesus monkeys were vaccinated with
3 doses of yeast recombinant P. vivax AMA1 adjuvanted with
SBAS2 (AS02A). These monkeys were then challenged with the
heterologous, yet closely related simian malaria parasite P.
cynomolgi. However, the course of infection of the AMA1
immunized animals was not different from the control group [10].
Recombinant AMA1 of the P. chabaudi rodent malaria parasite
also protected vaccinated mice against lethal challenge with a
homologous strain of P. chabaudi, but no protection was observed
against a heterologous strain [11]. As above in primate models, the
vaccine efficacy in the rodent models correlated with antibody
titers [12] and protection was also conferred upon passive transfer
of IgG. Antibodies against conformational epitopes were critical
for this protective response [11]. Thus, AMA1 based protection
appears to correlate best with antibody levels against conforma-
tional epitopes that are strain specific.
More recently and of greater relevance, Aotus monkeys were
vaccinated with a recombinant P. falciparum FVO strain AMA1
protein adjuvanted with Freund’s complete/incomplete adjuvant
[13]. Following challenge with the homologous FVO strain of P.
falciparum, 9 of 9 control animals developed high parasitemia and
required drug treatment within 15 days of challenge. Of the 6
AMA1 vaccinated animals, 3 showed strong indications of
protection (2 were subpatent and 1 had delayed patency). The
remaining 3 monkeys developed rapidly rising parasitemia and
required treatment for either high parasitemia or anemia. Efficacy
as measured by reduced parasite burden was 3/6 (50%) and as
measured by sterile protection was 2/6 (33%) [13]. Although, the
two monkeys that showed sterile immunity had high ELISA titers,
a third monkey with comparable ELISA titer was not protected in
the study.
Based on the promising preclinical evidence, Walter Reed Army
Institute of Research has developed a 3D7 AMA1 vaccine [2].
This vaccine is under advanced stages of clinical evaluation for
efficacy in humans [14,15]. A recent study showed that while the
AS01B and AS02A adjuvanted vaccine did not induce protection
in humans upon challenge, both had a slight effect on the growth
rate of the homologous strain parasite in the blood as observed by
quantitative PCR [16]. We present here results from an
immunogenicity and efficacy trial with the 3D7 AMA1 vaccine
in an Aotus nancymaae monkey model, conducted at the Centers for
Disease Control (Atlanta GA). Two human-use adjuvants,
Montanide ISA720 and AS02A were used in the trial. Since the
3D7 strain of P. falciparum does not invade Aotus RBC’s [17], two
heterologous parasite strains, FCH/4 and FVO, were used for the
challenge [18,19], the former strain being much more homologous
to 3D7 than the latter strain.
Materials and Methods
Ethics Statement
This study was approved by the CDC Institutional Animal
Care and Use Committee. Animals were housed at a CDC
primate facility fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC). Aotus monkeys were pair housed,
under space recommendations for lab animals set forth by the
Care and Use of Laboratory Animals, NIH. Monkeys were fed a
diet that was shown to provide adequate nutrition and calories
in captive Aotus used in malaria research. Animals were weighed
at weekly intervals and treated for veterinary problems as
they arose by an attending veterinarian. All observations were
recorded and entered into a computer database. Blood
collections of no more than 5% of a monkey’s total blood
volume were made by venipuncture and taken biweekly.
Persons responsible for handling the monkeys and reading
smears for parasitemia did not know the group to which the
animal was assigned. All vaccine formulations were free of
endotoxin and only human-use adjuvants were used in the
study. Monkeys that developed high-density parasitemia
(.200,000 parasites/mL of blood) or anemia (hematocrit below
20%) were cured with drugs and treated by iron supplemen-
tation and transfusion of whole blood.
Animals and Parasites
Following an initial quarantine period monkeys with intact
spleens and no history of Plasmodium infection were selected for
the study. Monkeys were in good health, free of tuberculosis and
weighed between 700–1000 g at the start of the study. Thirty
animals were stratified into groups of six animals according to
weight and sex. Groups were then assigned randomly to the
vaccine and control groups. Challenge infection was conducted
using two Aotus monkey adapted P. falciparum strains. The FCH/
4 strain was isolated in the Philippines and produces a
moderately virulent infection in spleen intact Aotus nancymaae
monkeys with ,50% of monkeys requiring antimalarial
treatment following an acute rapidly rising parasitemia. The
other ,50% of animals resolve the parasitemia before reaching
200,000 parasites per mL of blood [18]. The Vietnam Oak Knoll
(FVO) strain was isolated from a soldier returning from
Vietnam and produces a highly virulent infection with .90%
of spleen intact Aotus nancymaae requiring antimalarial treatment
[19].
Vaccine
The recombinant 3D7 AMA1 vaccine comprising amino acid
number 83–531 was expressed in E. coli [20]. The 3D7 AMA1
protein used in this trial was produced under GMP conditions, at
the WRAIR bioproduction facility. The process used for
manufacturing the antigen was essentially as described in Dutta
et al. 2001 [20], with one exception, the host E. coli strain used for
protein expression was Tuner(DE3)
TM and not Origami(DE3)
TM
(Invitrogen, Carlsbad CA). The vaccine met the purity criteria for
human-use injectables. Residual endotoxin content of the vaccine
was 0.004 EU/mg protein by gel clot assay and purity of the
protein was .95% by SDS-PAGE. The protein solution was
transported from WRAIR, Silver Spring MD to CDC Atlanta GA,
on dry-ice. Figure 1 shows the high level purity of the vaccine
protein by SDS-PAGE under non-reducing and reducing
conditions, and evidence of correct folding is shown by positive
reactivity of the non-reduced protein to a conformation dependent
monoclonal antibody 4G2dc1[21].
Protection against Malaria
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Recombinant 3D7 AMA-1 protein was formulated with either
Montanide ISA720 (ISA) (Seppic Inc, Paris) or AS02A (Glax-
oSmithKline Biologicals, Rixensart, Belgium) Adjuvant System.
For ISA720 formulation the antigen in PBS was mixed with the
adjuvant in the ratio of 30:70 v/v and vortexed for 10 min to form
a thick emulsion. For the AS02A formulation, the lyophilized
antigen was directly suspended in 0.5 ml of the adjuvant. The
control vaccine consisted of PBS formulated with ISA720. Three
doses of the vaccine, each containing 40 mg of AMA1 were
administered intra-muscular on days 0, 28 and day 84, 0.25 ml
vaccine on each thigh. Immunization sites were monitored daily
for adverse local reaction and the weight of the animals was
recorded at 4 wk interval during the study. Animals were bled for
preparation of serum, complete blood counts and on defined
occasions for clinical laboratory values, every two weeks beginning
four weeks before the first immunization and continuing until the
study was completed.
Challenge and Determination of Parasitemia
Three groups of six monkeys were challenged with FCH/4
strain parasites; the groups designated as PBS+ISAFCH/4,
AMA+ISAFCH/4 and AMA+AS02A-FCH/4. Two other groups
were challenged with FVO strain parasites; these were design-
ated as PBS+ISAFVO and AMA+ISAFVO. Ring-stage parasitized
erythrocytes from a donor monkey were diluted in sterile RPMI
1640 tissue culture medium. On day 112 of the study 50,000 and
10,000 ring stage parasites of the FCH/4 and FVO strain,
respectively, were administered intravenously into the monkeys via
injection into the femoral vein. Beginning 3 days after the
intravenous challenge, Giemsa-stained blood smears were made to
establish the number of parasites per mL blood by the quantitative
thick film or by thin film, when parasite counts exceeded
,80,000/ mL [19]. Daily blood smears were prepared and
evaluated for 56 days after the FVO and FCH/4 challenge.
Monkeys that developed high-density parasitemia (.200,000
parasites/mL of blood) were treated with mefloquine (Roche
Laboratories, Nutley, N.J.) and quinine (Marion Merrel Dow, Inc.,
Kansas City, Kans.). Animals that developed anemia were cured
with drugs and treated by iron supplementation and transfusion of
whole blood if the hematocrit fell below 20%. Iron supplemen-
tation is a standard practice by veterinary staff for the treatment of
malaria-induced anemia.
ELISA
Plates coated with either 3D7 or FVO AMA-1 (50 ng/well)
were blocked with 5% BSA-PBS for 1 hr. Aotus sera were serially
diluted four-fold starting from 1:1000 dilution and 75 ml of the
dilution was incubated in the wells for 2 hrs at room temperature.
The plates were washed thrice with PBS+0.05% Tween-20. Anti-
A. nancymaae IgG heavy-plus-light chain peroxidase-labeled
conjugate was diluted 1:10,000 in PBS-Tween and 50 ml/well
was incubated for 1 h at room temperature. Plates were washed
and developed by the addition of 50 ml of 2,29-azino-bis3-ethyl
benzthiazoline-6-sulfonic acid (ABTS) peroxidase substrate system
(KPL, Gaithersburg, MD). The optical density at 415 nm (OD415)
was measured after 30 min using a microplate reader (Molecular
Dynamics, Sunnyvale CA). The antibody endpoint titer was
calculated as the serum dilution that produced an OD415 of 0.5
absorbance units in the ELISA assay using a 4 parameter curve
fitting model in the Softmax software (Molecular Dynamics). The
0.5 OD405 fell in the linear part of the dilution curve.
Expression of Chimeric Proteins and Domain ELISA
AMA1 consists of 3 disulphide bonded domains, D1, D3 and
D3 [22]. In order to map the immune response to the various
domains of AMA1, we produced 5 chimeric proteins. These
chimeric proteins display the individual P. falciparum 3D7 AMA1
D1, D2, D3, D1+2 and D2+3o naP. berghei scaffold. The design,
expression and purification of the chimeric proteins will be
described elsewhere. The domain ELISA utilized the chimeric
AMA1 proteins as coat antigens. Various chimeras at 50 ng/well
were coated on the ELISA plates and the assay was done as above.
IFA
IFA slides were prepared from FVO and 3D7 asexual parasites
grown to mature schizonts in vitro by depositing the infected
erythrocytes into the wells and drawing the excess solution leaving a
thin layer of cells that were allowed to air dry. Prepared slides were
stored at 280uC until thawed for use in the IFA analysis. Sera were
diluted 1:32 with 0.01M PBS, pH 7.2, and two fold dilutions
continuingto 1:65,536 were placedin the wellsfor 1 hour in a moist
chamber. Slides were washed in PBS and a 1:100 dilution of FITC-
labeled goat anti-Aotus monkey IgG was incubated in each well for
another 1 hour in a moist chamber in the dark. After a second
washingcycletheslidesweredried,anti-fademountingmediumwas
applied and cover slip was mounted. Slides were then examined
under a UV microscope. The dilution in the last well showing
distinct fluorescence was taken as the IFA titer.
Figure 1. Recombinant 3D7 AMA1 vaccine was pure and folded
correctly. Left panel shows a coomassie blue stained SDS-PAGE
analysis of the 3D7 AMA1 vaccine under non-reducing (NR) and
reducing conditions (Red). Right panel shows positive reactivity of only
the non-reduced 3D7 AMA1 protein with a conformational monoclonal
antibody 4G2dc1.
doi:10.1371/journal.pone.0008138.g001
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Sera were thawed at 37uC in a water bath and heat inactivated
for 20 minutes at 56uC. Ring stages at 0.2% parasitemia and
normal RBC at 2% hematocrit were seeded in a 96 well plate with
a final culture volume of 40 ml. Sera was tested at a final
concentration of 10% against the 3D7 strain of P. falciparum and
5% against the FVO strain in a one cycle GIA (FVO was inhibited
by normal Aotus sera above 5% v/v). The plate was sealed in a gas
filled plastic bag and incubated under static conditions for 40 hrs
[23]. Ring stages of the parasite were stained by adding 5 ml of the
culture to 500 ml of 0.25X SYBR green dye in pH 7.4 PBS
containing 10 mM EDTA and 10 mM glucose [23,24]. Following
45 minute incubation in a shaking incubator maintained at 37uC,
parasites were quantified by flow-cytometry (488/530 nm) using a
BD FACScalibur (Franklin Lakes, NJ) gated on forward scatter for
40,000 RBC. Percent inhibition of invasion was calculated as,
[1-(percent ring stage parasitemia in test well/percent ring stage
parasitemia in pre-immune serum containing control well)].
Statistical Analysis
Data for the three FCH/4 challenged groups was evaluated by
analysis of variance to discern if differences existed among the
various groupings of data; multiple group comparisons were then
made by Tukey’s posttest. Data of the 2 FVO challenged groups
were compared by Mann–Whitney U test. Correlation between
Log ELISA and cumulative day 11 parasitemia were established
using the Spearman rank correlation. Plots were produced using
Prism Graphpad (La Jolla, CA) or Microsoft Excel software
(Redmond, WA).
Results
Sequence Differences between the Vaccine and
Challenge Strain AMA1 Proteins
It was necessary to examine the potential protective effects of
the human 3D7 vaccine against heterologous strains of P.
falciparum, FCH/4 and FVO, because P. falciparum 3D7 parasite
is not adapted to grow in Aotus monkeys. There are 12 amino acid
differences between FCH/4 and 3D7 AMA1 as compared to 24
amino acid differences between FVO & 3D7 AMA1 (Figure 2, top
panel). Since the 3D7 AMA1 vaccine consisted of amino acids 83–
531 (grey cells in Figure 2), the sequence differences between the
vaccine and the target strain within this sequence boundary were
mapped to the crystal structure of AMA1 [25,26] (Figure 2,
bottom panel). Eighteen of the 24 3D7-FVO amino acid
differences localized to domain-1 as compared to 3 out of the 12
3D7-FCH/4 differences. Hence, the 3D7 and FCH/4 domain-1
and domain-2 sequences are very similar. Within domain-1 the
Figure 2. The FCH/4 strain AMA1 is more homologous to 3D7 AMA1 as compared to FVO strain AMA1. Top panel shows the amino acid
differences between 3D7, FVO and FCH/4 AMA1. Polymorphisms within the grey cells are included in the sequence boundary of 3D7 AMA1 vaccine,
amino acid 83–531. The disulphide bonded domains (D1, D2 and D3) are marked by thick lines. D1 (amino acid 95–300), D2 (308–404) and D3 (439–
584). Lower panel shows the crystal structure of AMA1 (amino acids 97–531) with the location of the 3D7-FVO (left) and 3D7-FCH/4 (right) amino acid
differences shown as solid balls (D1 polymorphisms - red; D2 - green and D3 polymorphisms - blue). The residues of the C1 cluster (187, 190, 196, 197,
200, 204, 206 and 225) are circled in green.
doi:10.1371/journal.pone.0008138.g002
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polymorphisms within a three dimensional cluster termed C1,
shown in Figure 2 as circled residues [27]. One of the 3D7-FCH/4
differences (residue 187) mapped to C1 as compared to 8 of the
3D7-FVO differences (residue numbers 187, 190, 196, 197, 200,
204, 206, 225). It was anticipated that the 3D7 vaccine was more
likely to be effective against the C1-similar FCH/4 strain.
Reactogenicity and Immunogenicity
The 3D7 AMA1 vaccine formulated with either ISA or AS02A
adjuvants was well tolerated by the non-human primates, with no
indication of vaccine induced weight loss and only minor local
reactions, primarily with ISA. Two of the monkeys died during the
course of vaccination due to causes unrelated to the vaccine
antigen; both deaths occurred in the PBS+ISAFVO control group.
Monkey AI-3190 died suddenly 10 days post the first immuniza-
tion with PBS+ISA. Necropsy and histology revealed no or
minimal pathology with the exception of a mild chronic interstitial
nephritis. Monkey AI-3205 died 3 days prior to challenge after
three immunizations with PBS+ISA. Histology indicated a severe
sclerosing glomerulonephritis and the animal was under treatment
with Lasix. These deaths were judged to be unrelated to the
immunizations; acute and chronic nephritis are common in Aotus
monkeys [28].
ELISA. Sera collected on the day-of-challenge were assayed
using 3D7 AMA1 coated plates. The AMA+ISAFCH/4 titers
ranged between 26,000–2,000,000 (median=236,178) and the
AMA+AS02A-FCH/4 group titers ranged between 45,000–260,000
(median=73,773). Although the mean titer of AMA+ISAFCH/4
group (577,456) was 5 times higher than AMA+AS02A-FCH/4
group (116,423), this difference was not statistically significant
(Figure 3, left panel and Table 1). The mean titer of the FVO
challenged AMA+ISAFVO group was 303,034 on 3D7 AMA1
coated plates and significantly lower, 69,696, against the
heterologous FVO AMA1 plate antigen (Mann Whitney U test
p=0.02) (Figure 3, middle panel and Table 1).
IFA. Immuno-fluorescence titers of the day-of-challenge
sera are shown in Table 1. The AMA+ISAFCH/4 group IFA
titers ranged between 4,096–65,536 (median=12,288). The
AMA+AS02A-FCH/4 group titers ranged between 1,024–8,192
(median=6,144). Although the mean IFA titer of AMA+ISAFCH/4
group (22,528) was 4 times higher than that of the AMA+
AS02A-FCH/4 group (5,291) this difference also did not reach
statistical significance as was observed with ELISA titers. The
mean IFA titer of the FVO challenged AMA+ISAFVO group was
8,533 against 3D7 schizonts and significantly higher than the
2,219 titer against the heterologous FVO schizonts (Mann-
Whitney U test p=0.01).
GIA. The day-of-challenge sera of the FCH/4 challenged
groups were analyzed for their ability to inhibit invasion of 3D7
strain merozoites using growth inhibition assay (GIA) (Figure 3, right
panel and Table 1). The mean GIA activity of AMA+ISAFCH/4
group was higher than both the control PBS+ISAFCH/4 and the
AMA+AS02A-FCH/4 group (ANOVA followed by Tukey’s multiple
comparison test, p,0.05). The mean GIA activity of AMA+
AS02A-FCH/4 group sera was indistinguishable from the PBS control
group. The sera from the AMA+ISAFVO group had GIA activity
similartotheAMA+ISAFCH/4group howevertheGIA activity against
the heterologous FVO target parasite was not detectable (Table 1).
Overall these results indicated that the 3D7 AMA1 vaccine was
inducing an efficient antibody response in Aotus monkeys, with
higher levels of antibody detected with the ISA adjuvant, which
resulted in efficient inhibition of the homologous 3D7 parasites.
Levels of cross-reacting antibodies against FVO AMA1 protein
were ,5x lower, which was insufficient for in vitro growth
inhibition of the FVO parasite.
Analysis of Parasitemia Profiles
In order to determine if the 3D7 AMA1 vaccine had induced
protection against FCH/4 and FVO parasite challenge, parasit-
emia profiles were examined for individual animals within the
different immunization groups.
PBS+ISAFCH/4 group. Inoculation of 50,000 P. falciparum
FCH/4 strain parasitized RBC in the control PBS+ISAFCH/4
group led to detectable parasitemia in all monkeys by day 5 post
challenge. During the following days two different parasitemia
profiles were observed. Three monkeys (AI-3162, 3168, 3200;
solid lines in Figure 4) developed a rapidly rising ‘virulent’
parasitemia that required drug treatment within 15 days of
challenge. The peak parasitemia of AI-3162, AI-3168, AI-3200
Figure 3. AMA1+ISA vaccine formulation induced high titer antibodies that inhibited homologous parasite invasion. Left panel
shows ELISA endpoint titer of day-of-challenge sera and the group-mean (line). In the FCH/4 challenge group ELISA was done using 3D7 AMA1 coat
antigen and for the FVO strain challenge group, ELISA was done using 3D7 and FVO AMA1 coat antigens (shown in parentheses on the x-axis). Both
ELISA panels share the same y axis scale. Right panel shows the GIA activity of the day-of-challenge sera of the FCH/4 challenged groups measured at
10% serum concentration against 3D7 strain parasites.
doi:10.1371/journal.pone.0008138.g003
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ing monkeys (AI-3166, 3178, 3210; broken lines) had a rapidly
growing but ‘self-limiting’ parasitemia profile (defined as not
requiring drug treatment for high parasitemia), and eventually
becoming subpatent by day 24, 20, and 23, respectively. AI-3166
and AI-3210 had brief recrudescent infections by days 50 and 43.
Peak parasitemia in AI-3166, AI-3178 and AI-3210 were 78,300,
42,300 and 160,000 parasites per mL. The mean peak parasi-
temia of the 3 animals with virulent profile was 246,667/mL,
and that of the 3 animals with a self-limiting profile was
93,533/mL.
AMA+ISAFCH/4 group. Monkeys AI-3182 and AI-3226 had
the virulent parasitemia profile that required treatment on day 12
and 13 and thus were classified as not protected. Monkey AI-3191
had a self-limiting parasitemia profile reaching 168,000 parasites
per mL that was given anti-malarial treatment on day 19 due to
severe anemia and, therefore, was also not considered protected.
Monkey AI-3176, remained slide negative after the first challenge
and was then re-challenged with additional 50,000 parasi-
tized erythrocytes on day 16. AI-3176 remained smear-negative
throughout the trial showing sterile immunity. Monkey AI-3179
also showed protection, it had a short period of low level
parasitemia (,10 parasites/mL for 3 days) that self cured by day 8,
following which this animal remained subpatent. Monkey AI-3181
was patent (240 parasites/mL) only on day 4 and then remained
smear-negative. AI-3181 was also re-challenged on day 16 with
50,000 FCH/4 parasites, following which a parasitemic phase was
observed starting at day 24, peaking at 108,000 parasites per mL
on day 32, and then self-resolving by day 38. This monkey was
protected against the first challenge and as indicated by its sub-
patency and also against the re-challenge as indicated by a delay in
patency (7 days vs. 3–4 days).
AMA+AS02A-FCH/4 group. All animals of the AMA+
AS02A-FCH/4 group became smear positive between day 4 and
day 6. Although no sterile protection was observed, the parasitemia
profiles indicated that all 6 monkeys mirrored the self-limiting
parasitemia profile (not requiring drug treatment for high
parasitemia .200,000/mL) as compared to 3 of 6 in the control
group (Figure 4). Peak parasitemia ranged from 44,600 to 192,000
per mL. Monkeys AI-3057 and AI-3211, despite a self-limiting
Table 1. Immunogenicity and efficacy data of individual animals.
Group Animal ELISA (X1000) IFA GIA Parasites/mL (day 4–11)
3D7 FVO 3D7 FVO 3D7 FVO Mean Cumulative Peak
PBS+ISA FCH/4 AI-3162 0.3 0.3 64 64 7% nd 52016 416130 280000
AI-3166 0.3 0.5 128 64 16% nd 23996 191970 59580
AI-3168 0 0.3 ,32 32 27% nd 68358 546860 296000
AI-3178 0.1 0.5 32 ,32 0% nd 11468 91740 42300
AI-3200 0.3 0.3 32 32 0% nd 28413 227300 116000
AI-3210 0.3 0.2 ,32 ,32 26% nd 55668 445350 160000
AMA+AS02A FCH/4 AI-3057 70 36 4096 512 16% nd 37246 297970 164000
AI-3172 78 17 8192 256 10% nd 12860 102880 72000
AI-3177 261 133 8192 2048 57% nd 789 6310 4320
AI-3063 197 83 8192 4096 56% nd 9558 76460 44000
AI-3195 45 25 2048 256 11% nd 7485 59880 15840
AI-3211 48 30 1024 128 8% nd 1461 11700 7650
AMA+ISA FCH/4 AI-3176 2015 481 32768 8192 85% nd 0 0 0
AI-3179 912 352 16384 4096 84% nd 4 30 10
AI-3181 309 144 65536 4096 77% nd 30 240 240
AI-3182 163 116 8192 4096 59% nd 20498 163980 105000
AI-3191 40 14 8192 128 22% nd 43531 348250 140000
AI-3226 26 18 4096 1024 35% nd 26935 215490 84000
PBS+ISA FVO** AI-3054 0.3 0.7 64 64 13% 4% 107451 859610 640000
AI-3163 0.8 0.7 256 256 211% 0% 11843 94740 87000
AI-3185 0.3 0.4 128 128 13% 5% 60233 481860 288000
AI-3199 0.3 0.3 32 32 22% 21% 94416 755330 520000
AMA+ISA FVO AI-3055 733 129 16384 2048 63% 4% 162510 1300080 1040000
AI-3173 140 44 8192 2048 24% 22% 38165 228990 208000
AI-3174 557 134 8192 1024 67% 15% 17030 136240 56000
AI-3193 232 52 8192 2048 48% 2% 54651 437210 320000
AI-3203 57 29 8192 4096 6% 0% 63575 508600 400000
AI-3209 98 31 2048 2048 8% 3% 55638 445110 348000
Vaccine and challenge groups, animal ID, ELISA endpoint titer against 3D7 or FVO AMA1 coated plates, IFA titer against 3D7 and FVO schizonts, GIA activity against P.
falciparum 3D7 or FVO target parasite and parasite burden (mean, peak and cumulative counts) between days 4 and 11 post challenge are shown. ** Two animals in the
PBS+ISAFVO group died due to unrelated causes during the vaccination phase. GIA was not done (nd). The ELISA titer values are 1000X.
doi:10.1371/journal.pone.0008138.t001
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respectively,duetosevereanemia.Thus,thisgroup perhapsshowed
a degree of partial protection. However the mean peak parasitemia
of the six self-limiting parasitemia profile monkeys in the
AMA+AS02A-FCH/4 group (130,773/mL), was not different from
the 3 control group animals (93,533/mL) that had a self-limiting
profile (2 tailed t-test, p=0.6). PBS+ISAFVO group: There were only 4
animals in the control PBS+ISAFVO group at the time of challenge
due to the death of 2 monkeys during the vaccination phase.
Infection induced by inoculating 10,000 FVO strain parasitized
RBC led to a rapidly rising virulent parasitemia profile in all 4
control monkeys with anti-malarial drug cure given between day 11
and 13 (Figure 4).
AMA+ISAFVO group. All of the 6 animals had a virulent
parasitemia profile comparable to the PBS+ISAFVO control group.
Five monkeys had to be treated for high parasitemia on day 9 or
11. One other monkey (AI-3174) peaked at 112,000 parasites/mL
and on day 19 was treated with MQ and quinine for infection and
Figure 4. Parasitemia profiles of FCH/4 and FVO challenged groups. Daily parasitemia of animals plotted against days-post-challenge (days).
Solid lines represent a virulent parasitemia profile that required drug treatment for high parasitemia (.200,000/mL) within 15 days of challenge.
Broken lines represent a slower progressing and self-limiting infection profile. The challenge strains are indicated in parentheses (FCH/4 or FVO). Two
monkeys in the AMA+ISAFCH/4 group (AI3181, AI-3176) were re-challenged on day 16.
doi:10.1371/journal.pone.0008138.g004
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FVO strain challenge (Figure 4).
Parasite Burden and Correlates of Protection
Mean, peak and cumulative parasite levels were determined for
group-wise comparisons. The first monkey in the FCH/4
challenged groups became parasitemic on day 4 and was drug
treated on day 11, hence the relative parasite burden of the FCH/4
challenged groups was compared between days 4–11 (Figure 5 and
Table 1). There was a trend towards lower mean, peak and
cumulative parasitemia in the AMA+ISA and AMA+AS02A groups
compared to the controls. However this difference in parasite
burden did not reach statistical significance (p values for ANOVA
for repeated measures design for mean, peak and cumulative
parasitemia was 0.06, 0.08 and 0.06 respectively). For the FVO
challenge groups the mean, peak and cumulative parasitemia
between days 4–11 of the AMA+ISAFVO and the PBS+ISAFVO
groups were compared by Mann-Whitney U test (not plotted). No
difference in the parasite burden was observed between the vaccine
and the control group following FVO parasite challenge.
A plot of the mean cumulative parasitemia revealed further
differences between the FCH/4 challenged groups (Figure 6, left
panel.) The rate of parasite growth indicated by the steepness of
the cumulative parasitemia curve indicated that AMA1 vaccine
had slowed the rate of FCH/4 multiplication in both the adjuvant
groups as compared to the PBS control vaccine. The mean
cumulative parasitemia on day 11, for the PBS-ISAFCH/4 group
(319,892) was higher than the AMA+ISAFCH/4 group (121,332;
Mann-Whitney U test p=0.06), and the AMA+AS02A-FCH/4
group (92,533, p=0.02). Among the 2 FVO strain challenged
groups, there was no difference in the growth rates between the
AMA1-vaccinated and the control group (Figure 6, right panel).
In this study, 18 animals in 3 groups were challenged with
FCH/4 strain. Three monkeys in the AMA+ISAFCH/4 group were
protected: AI-3176 and AI-3179 had greatly reduced or no
parasite burden and AI-3181 had a delayed parasitemic phase.
The GIA activity of serum from these 18 monkeys was plotted
against the log ELISA titer (Figure 7, left panel). Sera from these
three monkeys had .70% GIA activity, .300,000 ELISA titer
and IFA titer .8,192 (Table 1). There was also a negative
correlation between the cumulative parasitemia on day 11 and the
log ELISA endpoint titer (Figure 7, right panel). Spearman rank
test confirmed the statistical significance of this correlation (rho
factor r=20.780 and p=0.000134).
Domain-Wise Mapping of Antibody Responses
To determine the differences in specificity of antibodies induced
by the two adjuvants, and to explore if a particular domain-specific
pattern correlated with protection, chimeric AMA1 proteins were
used to determine the ELISA end-point titer against 3D7 AMA1
domains-1, 2, 3, 1+2 and 2+3 (termed D1, D2, D3, D1+2, D2+3
proteins respectively). The mean end-point titer of 12 AMA1
vaccinated monkeys against the protein chimeras D1, D2, D3,
D1+2 and D2+3 were 45053, 48971, 14708, 103803 and 56107
respectively. Although, the contribution of antibodies that cross-
react with the P. berghei AMA1 in this mapping analysis cannot be
ruled out, the mean endpoint titer of the 12 monkeys against the
recombinant scaffold protein P.berghei AMA1 was significantly
lower, 3202, than the chimeric proteins that display PfAMA1
epitopes. To normalize the individual animal titers, the domain-
specific end-point titer was expressed as a percentage of the titer
against the full-length AMA1 protein. The mean domain-specific
titer of AMA+AS02A-FCH/4 and AMA+ISAFCH/4 groups was
plotted in Figure 8. Analysis of variance, followed by Tukey’s
posttest showed no difference in domain specificity of antibodies
induced by AS02A vs. ISA70 adjuvant. Among the single domains,
the reactivity pattern was D1=D2.D3 and among the double
domains, reactivity pattern was D1+2.D2+3. Proportion of
antibodies against the D1+2 was highest between the domains
and was statistically indistinguishable from the titer against the full-
length antigen for both AMA+ISA and AMA+AS02A groups
(Tukeys multiple comparison, p.0.05), indicating that the
majority of the antibodies that bind to the full-length antigen
recognize epitopes formed by residues present on domains 1 and 2.
Figure 9 shows the end-point titers of all 12 AMA1 vaccinated
and FCH/4 challenged monkeys. Individual serum titers showed
that protection did not correlate with a unique domain specific
antibody induction pattern, instead the titers in the AMA+AS02A
group were generally lower against all domains and the protected
monkeys (AI-3176, AI-3179 and AI-3181) had D1+2 titers
exceeding 100,000 (Figure 9), suggesting that magnitude of
antibody response to the full-length AMA1 and domains1+2 are
a critical correlate of AMA1 based protection.
Discussion
The 3D7 strain of Plasmodium falciparum grows vigorously in vitro
and was used for the first genome sequencing of a malaria parasite
[29]. This strain of P. falciparum also produces gametocytes and its
sensitivity to chloroquine has made it an excellent choice as a
Figure 5. 3D7 AMA1 vaccination reduced the parasite burden of the FCH/4 strain. Mean, peak and cumulative parasitemia (parasites/mL) of
individual animals and their mean (line) between days 4–11 post challenge.
doi:10.1371/journal.pone.0008138.g005
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numerous attempts made at the CDC Atlanta by Dr. William
Collins and others, the 3D7 parasite could not be adapted to grow
in the New World monkey models (personal communication).
Hence, in order to test the efficacy of a 3D7 strain based AMA1
vaccine, we utilized two heterologous strains FCH/4 and FVO.
The FVO strain is highly virulent in Aotus nancymaae, whereas,
the FCH/4 strain is less well adapted. In this study, a dose of
50,000 FCH/4 strain parasites produced virulent infection
requiring drug treatment in 3 of 6 animals in the control group,
while the remaining 3 animals self-cured after developing high
parasitemia (Figure 4). In comparison, only 10,000 parasites of the
FVO strain were sufficient to produce a rapidly rising virulent
infection in 4 of 4 control monkeys, all of which required drug
treatment (Figure 4). Positive efficacy of the AMA+ISA vaccine
against a FCH/4 strain challenge was observed where protection,
as measured by a reduced parasite burden, was 50% and as
measured by sterile protection, was 16% (Figure 4, 5 and 6). The
animals in the AMA+AS02A group had a reduced rate of
parasitemia increase that did eventually reach a high mean peak
parasitemia that was surprisingly higher than the parasitemia of
the control group monkeys with a self-limiting profile. None of the
animals in the AMA+AS02A group needed treatment for the
hyper-parasitemia, although two were treated for severe anemia.
ELISA and IFA titers showed that anti-3D7 AMA1 antibodies had
lower recognition of the FVO strain AMA1, and, this was
associated with 0% efficacy of the AMA+ISA vaccine against the
more virulent FVO strain.
Although FCH/4 is less virulent than the FVO strain, it was
chosen as a one of the two challenge strains because it was the
nearest in amino acid sequence of AMA1 to 3D7 among a group
of monkey adapted P. falciparum strains available for challenge
Figure 6. 3D7 AMA1 vaccination slowed growth rate of FCH/4 but not FVO strain. Group-wise mean cumulative parasitemia of the FCH/4
(left panel) and FVO (right) challenged animals plotted against days post challenge. Solid line, PBS control group; broken line, AMA+ISA; dotted line,
AMA+AS02A.
doi:10.1371/journal.pone.0008138.g006
Figure 7. ELISA titers positively correlate GIA activity and negatively correlate parasitemia. Left panel shows GIA activity of the FCH/4
challenged animals plotted against log ELISA titer. Group symbols: PBS+ISA (triangle), AMA+ISA (cross) and AMA+AS02A (square). The three monkeys
that were protected in the study had GIA activity of .70% and ELISA titer of .300,000, cut-off indicated by grey lines. Right panel shows the
correlation between log ELISA endpoint titer and the cumulative day 11 parasitemia for the 18 FCH/4 challenged animals.
doi:10.1371/journal.pone.0008138.g007
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between 3D7 and FCH/4 versus 3D7 and FVO was analyzed to
rationalize the observed pattern of heterologous protection. We
have previously shown that the antigenic escape residues of 3D7
AMA1 reside within a small three dimensional cluster called C1
[27] (Figure 2). This cluster contains the most polymorphic sites
(residues 187, 190, 196, 197, 200, 204, 206, 225) of AMA1.
Interestingly, only one amino acid difference between 3D7-FCH/
4 mapped to the C1 cluster (Figure 2), as compared to 8
differences between 3D7-FVO. Indeed, the majority of the
differences between 3D7 and FCH/4 in AMA1 mapped to
domain-3 (residues 448, 496, 503, 512). Published cross-strain
inhibition data using anti-3D7 antibodies against P. falciparum D10
strain target parasites has shown that three out of the four 3D7-
FCH/4 domain-3 amino acid differences confer no escape
advantage to the D10 strain parasite in a cross-strain GIA against
anti-3D7 AMA1 [31]. The FCH/4 strain was, therefore, an
appropriate choice to study the protective efficacy of 3D7 strain
AMA1 vaccine formulation.
The most likely cause of vaccine failure in the FVO challenged
animals was therefore antigenic escape from strain-specific 3D7
AMA1 antibodies. Alternatively, there may be differences in the
relative susceptibility of FCH/4 and FVO strains to invasion
inhibitory AMA1 antibodies. We have shown previously that
affinity purified antibody required for 50% invasion inhibition was
lower for the 3D7 strain parasite, as compared to the FVO strain
[27]. This suggested that FVO parasite may be inherently more
resistant to inhibition by anti-AMA1. Most importantly future
AMA1 vaccines need to be evaluated for their ability to inhibit
multiple strains of the parasite as well as some primary isolates that
may use multiple invasion pathways.
Three out of the 12 AMA1 vaccinated monkeys (compared to 0
of 6 adjuvant control monkeys) were strongly protected against a
relatively homologous, yet weak, challenge strain FCH/4. The
protected monkeys had the highest GIA activity, high IFA titer
and highest ELISA titer against full-length and domains1+2o f
AMA1. There was a negative correlation between mean parasite
count and ELISA titer and protection correlated with a threshold
antibody titer, which was achieved in some monkeys of the ISA720
group, but not in the AS02A group. An AMA+AS02A formulation
failed to induce sterilizing immunity in humans in a Phase 1/2a
trial [16], although it reduced the parasite growth rate, as was
observed for AS02A formulation group in this Aotus study. It is
difficult to compare the absolute antibody titers between species,
but GIA activity of the sera can be more accurately compared. In
the Phase1/2a trial, the mean GIA activity measured using 20%
v/v serum concentration against the 3D7 strain parasite was 30%
(range 10–40%) [16], which is concordant with a dose escalation
Phase 1 trial where the AMA+AS02A vaccine induced GIA
activity in the 30–40% range, also at 20% serum concentration
[14]. In a recently published human Phase 1 trial with FVO
AMA1 vaccine, adjuvanted with IS720 and AS02, the mean GIA
activity was in the 20–30% range at 10 mg/ml IgG [32], for both
adjuvant groups. The 10 mg/ml concentration is close to the
physiological concentration of IgG in the serum, and our data
suggests that significantly higher level of invasion inhibition
(.70% activity at one tenth the equivalent serum concentration,
Figure 8. Domain-specificities of AS02A and ISA720 induced
anti-AMA1 were similar. End-point titer was determined against
chimeric proteins displaying P. falciparum domains 1, 2, 3, 1+2o r2 +3
on P. berghei AMA1 scaffold (D1, D2, D3, D1+2, D2+3 chimeras
respectively). Domain-specific titer was calculated by expressing the
domain-specific end-point titer as a percentage of titer against the full-
length 3D7 AMA1 protein. Mean and standard error for 6 animals per
group was plotted.
doi:10.1371/journal.pone.0008138.g008
Figure 9. Domain1+2 end-point titer of protected animals exceeded 100,000. FCH/4 challenged AMA+AS02A and AMA+ISA group titers
against full-length 3D7 AMA1 (3D7) or chimeras D1, D2, D3, D1+2, D2+3 that display the corresponding P. falciparum 3D7 strain AMA1 domains on a
P. berghei AMA1 scaffold (Pb). End-point titers against the P. berghei AMA1 scaffold protein are also plotted. Animals protected in the AMA+ISA group
(AI-3176, AI-3179 and AI-3181) had the highest D1+2 end-point titer (red dotted line).
doi:10.1371/journal.pone.0008138.g009
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Phase1/2a trial [16] also failed to cause cross-strain inhibition of
the FVO parasite, which was also observed in our non-human
primate study reported here.
Viral neutralization titer is generally defined as the serum
dilution that neutralizes 50% of virus. It is easier and more
accurate to titer out antibodies to a 50% end-point than to
measure higher levels of neutralization or inhibition directly.
Harmonization of assay protocols for several virus diseases has
allowed comparison of vaccine efficacy between trials. A 50%
plaque reduction neutralization titer of .120 (1:120 serum
dilution) correlates with protection against measles [33] and a
50% neutralization titer of .33 against the influenza virus also
correlates protection [34]. Our data suggests that 70% inhibition
(neutralization) at 1:10 serum dilution is adequate to protect
against a malaria challenge in Aotus monkeys. Limitations in
availability of Aotus sera did not allow us to use higher
concentrations of serum antibodies. We expect that antibodies in
undiluted sera would have greater than 90% inhibition of FCH/4
in GIA, although we cannot rule out other immune mechanisms.
This result is not surprising because the growth-rate of P. falciparum
parasites in vitro is between 6–15 fold per cycle, and a high level of
GIA activity is needed to induce solid protection. Thus far no
human-use vaccine formulation has met this GIA activity. If viral
neutralization titers are an indication, malaria vaccine formula-
tions need to generate significantly higher titers to induce sterile
protection. This may be further complicated by other anti-malaria
antibodies, prevalent in endemic populations, that block the anti-
AMA1 mediated invasion inhibition [35]. Future Aotus trials using
Montanide formulations of AMA1 can provide an opportunity to
confirm the current findings and to establish a cut-off ELISA titer/
GIA activity that human-use formulations must achieve, prior to
entering advanced human trials.
AMA1 antibodies also need to be capable of inhibiting invasion
across a broad range of parasite strains. A Phase 2b study using a
bi-allelic 3D7+FVO AMA1 vaccine in 300 Malian children,
showed no impact of vaccination on the frequency of parasitemic
episodes. The 3D7 based AMA1 vaccine used in our manuscript
has been evaluated in a series of clinical trials, culminating in a
Phase 2b trial in Mali, Africa, an area of significant P. falciparum
genetic diversity (Chris Plowe, University of Maryland, personal
communication). If the current generation of 3D7 and FVO
AMA1 based vaccines [36], fail to reduce parasite burden in
children, structural vaccinology [27] and population biology [37]
approaches will be needed to engineer a second generation
antigen, that induces higher titer of cross-reactive inhibitory
antibodies. Aotus monkey trials can serve as an important down
selection-criteria to make critical go-no-go decisions, prior to
testing the next generation of AMA1 based vaccines in humans.
Novel formulation and delivery platform selection studies can
benefit from a threshold GIA activity reported here, as a correlate
of AMA1 based protection in the Aotus model.
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